The healthcare industry has its share of ridiculous acronymsdont get us started on the Prometheus program (May 26, p. 17)but the news releases coming out of the recent European Society of Cardiology meeting in Munich bordered on parody.
There was the much awaited conclusion of the Beautiful ivabradine drug trial, whose acronym stands for (and, as humorist Dave Barry would say, were not making this up) morBidity-mortality EvAlUaTion of the IF inhibitor ivabradine in patients with CAD and left ventricULar dysfunction. Involved in the Beautiful trial were 10,917 coronary artery disease patients, or CADs, if you willthough it should be noted that the acronym may not be a true reflection of their character.
Researchers cited the results of the previous APPROVe, or Adenomatous Polyp Prevention on Vioxx, study when discussing an ongoing study known as the Precision trial, which stands for Prospective Randomised Evaluation of Celecoxib Integrated Safety vs. IbuprOfen and Naproxen.
And, at least a tuneful acronym was composed for the trial looking into better ways to diagnose the reasons for SOBs, or shortness of breath (hey, what did you think we were talking about?). The trial was known as the BACH study, which stands for Biomarkers in Acute Congestive Heart failure. And, of course, the BACH study was sponsored by a German company that wants to be known as BRAHMS, though Outliers is afraid to ask if thats actually an acronym, or if the firms just in love with capitals.